GD2 CAR-T cell therapy (Stanford University)

N/A

Report date: 2024/07/12 09:35:54

Base Information

Drug NameGD2 CAR-T cell therapy (Stanford University)
Drug Alias Nameanti-GD2 CAR T-cell therapy (Stanford University)GD2.BB.z.iCasp9-CAR T Cells (Stanford University)autologous anti-GD2 CAR T-cell therapy (Stanford University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionDisialoganglioside GD2 modulators
TargetsDisialoganglioside GD2
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesStanford University
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A